These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32414853)

  • 1. Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial.
    Dold SM; Möller MD; Ihorst G; Langer C; Pönisch W; Mügge LO; Knop S; Jung J; Greil C; Wäsch R; Engelhardt M
    Haematologica; 2021 Mar; 106(3):875-880. PubMed ID: 32414853
    [No Abstract]   [Full Text] [Related]  

  • 2. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.
    Engelhardt M; Domm AS; Dold SM; Ihorst G; Reinhardt H; Zober A; Hieke S; Baayen C; Müller SJ; Einsele H; Sonneveld P; Landgren O; Schumacher M; Wäsch R
    Haematologica; 2017 May; 102(5):910-921. PubMed ID: 28154088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.
    Engelhardt M; Dold SM; Ihorst G; Zober A; Möller M; Reinhardt H; Hieke S; Schumacher M; Wäsch R
    Haematologica; 2016 Sep; 101(9):1110-9. PubMed ID: 27479825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications.
    Schoeller K; Ihorst G; Reinhardt H; Holler M; Scheubeck S; Herget G; Wäsch R; Engelhardt M
    Haematologica; 2024 Apr; 109(4):1279-1284. PubMed ID: 38031759
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
    Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.
    Auner HW; Garderet L; Kröger N
    Br J Haematol; 2015 Nov; 171(4):453-62. PubMed ID: 26213240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.
    Gregersen H; Vangsted AJ; Abildgaard N; Andersen NF; Pedersen RS; Frølund UC; Helleberg C; Broch B; Pedersen PT; Gimsing P; Klausen TW
    Cancer Med; 2017 Jul; 6(7):1807-1816. PubMed ID: 28639741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome.
    Kleber M; Ihorst G; Gross B; Koch B; Reinhardt H; Wäsch R; Engelhardt M
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):541-51. PubMed ID: 23810244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
    Palumbo A; Sezer O; Kyle R; Miguel JS; Orlowski RZ; Moreau P; Niesvizky R; Morgan G; Comenzo R; Sonneveld P; Kumar S; Hajek R; Giralt S; Bringhen S; Anderson KC; Richardson PG; Cavo M; Davies F; Bladé J; Einsele H; Dimopoulos MA; Spencer A; Dispenzieri A; Reiman T; Shimizu K; Lee JH; Attal M; Boccadoro M; Mateos M; Chen W; Ludwig H; Joshua D; Chim J; Hungria V; Turesson I; Durie BG; Lonial S;
    Leukemia; 2009 Oct; 23(10):1716-30. PubMed ID: 19494840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.
    Quach H; Joshua D; Ho J; Szer J; Spencer A; Harrison S; Mollee P; Roberts A; Horvath N; Talaulikar D; To B; Zannettino A; Brown R; Catley L; Augustson B; Jaksic W; Gibson J; Prince HM
    Intern Med J; 2015 Mar; 45(3):335-43. PubMed ID: 25735577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
    Merz M; Kellermann L; Poenisch W; Tischler HJ; Kohnke J; Knauf W; Goldschmidt H
    Ann Hematol; 2017 Jun; 96(6):987-993. PubMed ID: 28409228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic effect of comorbidity indices in elderly patients with multiple myeloma.
    Bila J; Jelicic J; Djurasinovic V; Vukovic V; Sretenovic A; Andjelic B; Antic D; Todorovic M; Mihaljevic B
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):416-9. PubMed ID: 25873436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Labonté L; Iqbal T; Zaidi MA; McDiarmid SA; Huebsch LB; Tay J; Atkins H; Allan DS
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1039-1044. PubMed ID: 18721767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Disability on the Diagnosis and Treatment of Multiple Myeloma in Korea: A National Cohort Study.
    Kwon J; Kim SY; Yeob KE; Han HS; Lee KH; Shin DW; Kim YY; Park JH; Park JH
    Cancer Res Treat; 2020 Jan; 52(1):1-9. PubMed ID: 31010276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
    Siegel DS; Vij R; Jakubowiak AJ
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):1-15. PubMed ID: 21928467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
    Belotti A; Ribolla R; Cancelli V; Crippa C; Bianchetti N; Ferrari S; Bottelli C; Cattaneo C; Tucci A; De La Fuente Barrigon C; Rossi G
    Am J Hematol; 2020 Jul; 95(7):759-765. PubMed ID: 32242970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and developments in diagnosis and therapy of multiple myeloma.
    Hillengass J; Neben K; Goldschmidt H
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):151-5. PubMed ID: 19763621
    [No Abstract]   [Full Text] [Related]  

  • 18. Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?
    Moser S; Bacher U; Jeker B; Mansouri Taleghani B; Betticher D; Ruefer A; Egger T; Novak U; Pabst T
    Hematol Oncol; 2019 Dec; 37(5):649-651. PubMed ID: 31483507
    [No Abstract]   [Full Text] [Related]  

  • 19. Autologous Hematopoietic Cell Transplantation for Dialysis-Dependent Myeloma: More Efficient, Less Toxic.
    Amit O; Ram R
    Acta Haematol; 2018; 139(2):104-105. PubMed ID: 29414800
    [No Abstract]   [Full Text] [Related]  

  • 20. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.
    Mohyuddin GR; Faisal MS; Badar T; Shah N; Bashir Q; Patel KK; Hosing C; Popat UR; Rondon G; Delgado R; Shah JJ; Weber DM; Thomas SK; Manasanch EE; Orlowski RZ; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2018 Feb; 59(2):515-518. PubMed ID: 28673185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.